This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (11)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA

Gary C. Curhan, MD, ScD

JAMA. 2003;289:606-608.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Contrast nephropathy is one of the well-recognized risks of coronary angiography. Although the disease occurs infrequently with normal renal function, its frequency increases with decreasing renal function, ranging from 5% in patients with mild renal insufficiency¹ to 50% in those with severe renal dysfunction and diabetes.² Given that contrast nephropathy is associated with increased morbidity, mortality, and length of hospitalization, and possibly with long-term renal impairment,³ there is great interest in its prevention.

Several factors increase the risk of contrast nephropathy. Contrast-related factors include higher total dose and the use of ionic and high osmotic agents.³ Patient-related risk factors include renal dysfunction, diabetes mellitus, congestive heart failure, and reduced effective circulating volume.³

The mechanism by which contrast adminstration leads to renal injury is uncertain. Studies in humans suggest 2 potential pathways that may operate individually or together: renal vasoconstriction, resulting in medullary ischemic damage, and . . . [Full Text of this Article]

Author Affiliations: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.

RELATED LETTER

Acetylcysteine and Renal Function Following Coronary Angiographic Procedures
Albert Yuh-Jer Shen
JAMA. 2003;289(21):2794-2795.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Acetylcysteine for Prevention of Acute Deterioration of Renal Function Following Elective Coronary Angiography and Intervention: A Randomized Controlled Trial
Jay Kay, Wing Hing Chow, Tak Mao Chan, Sing Kai Lo, On Hing Kwok, Alex Yip, Katherine Fan, Chi Hang Lee, and Wai Fai Lam
JAMA. 2003;289(5):553-558.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: The CADILLAC Risk Score
Halkin et al.
J Am Coll Cardiol 2005;45:1397-1405.
ABSTRACT | FULL TEXT  

N-Acetylcysteine for the Prevention of Radiocontrast Induced Nephropathy: A Meta-Analysis of Prospective Controlled Trials
Kshirsagar et al.
J. Am. Soc. Nephrol. 2004;15:761-769.
ABSTRACT | FULL TEXT  

Contrast Nephropathy
Rezkalla
Clin Med Res 2003;1:301-304.
ABSTRACT | FULL TEXT  

Acetylcysteine and Renal Function Following Coronary Angiographic Procedures
Shen
JAMA 2003;289:2794-2795.
FULL TEXT